Shire and drug partner Xenetic have released new data for their collaborative bleeding disorder drug SHP656, and the news isn’t good.

Ablynx and Merck KGaA have moved their osteoarthritis candidate to the cusp of the clinic.

La Jolla Pharmaceutical has posted a full look at data from a phase 3 trial of its vasodilatory shock candidate LJPC-501.

Argenx’s IPO fundraising total has come to a stop at $144.7 million, more than 50% above its initial target.

RM Global has created a VC fund dedicated to the FutuRx biotech incubator Johnson & Johnson set up with OrbiMed and Takeda.

AB Science says its drug candidate masitinib has slowed down progression in a late-stage trial, but its checkered development history means the reaction is…

Iterum has completed a $65 million series B to equip it to take its antibiotic sulopenem through phase 3.

Verily hired former FDA chief Robert Califf, Theranos named a former Abbott Diagnostics exec as head of product development, Biogen's CSO quietly stepped…

In this week's EuroBiotech Report, AstraZeneca lays out its Brexit wish list, Bayer boards the FDA fast track, analysts lay into AB Science and more.

Biotech